VAN NOSTRAND ROBERT L
SEC insider (Form 3/4/5 filer). CIK 0001225198. Director at SELLAS Life Sciences Group, Inc. (SLS) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Jan 7, 2026. Located in NEW YORK, NY.
Companies VAN NOSTRAND ROBERT L has filed insider reports for
- SELLAS Life Sciences Group, Inc. (SLS): Director
- Intra-Cellular Therapies, Inc. (ITCI): Director
VAN NOSTRAND ROBERT L
CIK: 0001225198
Transaction Breakdown
Open Market Buys (P)1 (25.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)1 (25.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jan 7, 2026SLS
SELLAS Life Sciences Group, Inc.
AwardDirect50K shares- - Jun 12, 2025SLS
SELLAS Life Sciences Group, Inc.
PurchaseDirect10K shares at avg. $1.48$15K - Apr 2, 2025ITCI
Intra-Cellular Therapies, Inc.
DispositionDirect11.3K shares at avg. $132.00$1.5M - Jan 10, 2025SLS
SELLAS Life Sciences Group, Inc.
AwardDirect12.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 7, 2026 |  SLS SELLAS Life Sciences Group, Inc. | Award | 50,000 | - | $0 | Direct |
| Jun 12, 2025 | SLS SELLAS Life Sciences Group, Inc. | Purchase | 10,000 | $1.48 | $14,800 | Direct |
| Apr 2, 2025 |  ITCI Intra-Cellular Therapies, Inc. | Disposition | 11,340 | $132.00 | $1,496,880 | Direct |
| Jan 10, 2025 | SLS SELLAS Life Sciences Group, Inc. | Award | 12,500 | - | $0 | Direct |
1-4 of 4 transactions